Troriluzole Shows Promise in Spinocerebellar Ataxia Type 3 Subgroup Despite Failing to Achieve Prima...
Troriluzole Shows Promise in Spinocerebellar Ataxia Type 3 Subgroup Despite Failing to Achieve Primary End Point
About this item
Full title
Author / Creator
Publisher
Cranbury: MultiMedia Healthcare Inc
Journal title
Language
English
Formats
Publication information
Publisher
Cranbury: MultiMedia Healthcare Inc
Subjects
More information
Scope and Contents
Contents
Newly announced findings from a phase 3 study (NCT03701399) evaluating troriluzole (Biohaven Pharmaceuticals), an investigational therapy to treat spinocerebellar ataxia (SCA), showed that the agent failed to reach statistical significance on its primary end point; however, there were numerical treatment benefits observed in a subgroup of those wit...
Alternative Titles
Full title
Troriluzole Shows Promise in Spinocerebellar Ataxia Type 3 Subgroup Despite Failing to Achieve Primary End Point
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_reports_2802942944
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_reports_2802942944
Other Identifiers
ISSN
2767-4258
E-ISSN
2767-4266
